Baton Rouge, LA2 Active Studies

Peripheral Artery Disease Clinical Trials in Baton Rouge, LA

Find 2 actively recruiting peripheral artery disease clinical trials in Baton Rouge, LA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
659
Enrolling

Recruiting Peripheral Artery Disease Studies in Baton Rouge

About Peripheral Artery Disease Clinical Trials in Baton Rouge

Peripheral artery disease (PAD) is a circulatory condition where narrowed arteries reduce blood flow to the limbs, especially the legs. Common symptoms include leg pain when walking (claudication). Treatment includes lifestyle changes, medications, and sometimes procedures to improve blood flow.

There are currently 2 peripheral artery disease clinical trials recruiting participants in Baton Rouge, LA. These studies are seeking a combined 659 participants. Research is being sponsored by SurModics, Inc., Avantec Vascular. Clinical trial participation is free and participants receive study-related medical care at no cost.

Peripheral Artery Disease Clinical Trials in Baton Rouge — FAQ

Are there peripheral artery disease clinical trials in Baton Rouge?

Yes, there are 2 peripheral artery disease clinical trials currently recruiting in Baton Rouge, LA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Baton Rouge?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Baton Rouge research site will contact you about next steps.

Are clinical trials in Baton Rouge free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Baton Rouge studies also compensate for your time and travel.

What peripheral artery disease treatments are being tested?

The 2 active trials in Baton Rouge are testing new therapies including novel drugs, biologics, and treatment approaches for peripheral artery disease.

Data updated July 21, 2026 from ClinicalTrials.gov